Arnold S. Freedman, MD

    Arnold S. Freedman, MD

    Professor of Medicine at Harvard Medical School and from the Department of Medical Oncology at the Dana-Farber Cancer Institute in Boston, MA

    You Make the Call

    • Would you restart rituximab as part of a new chemotherapy regimen for this patient with DLBCL? Thursday, December 1st, 2016

      Arnold S. Freedman, MDProfessor of Medicine at Harvard Medical School and from the Department of Medical Oncology at the Dana-Farber Cancer Institute in Boston, MA This month, Arnold S. Freedman, MD, answers a question about restarting rituximab as part of a new chemotherapy regimen for a patient with diffuse large B-cell lymphoma. Clinical Dilemma: In [...]

    back to top
    SHARE